MDT Stock Dips 0.10% Despite Strong Q3 Earnings and Positive Revenue Growth

Medtronic Public Limited Company (MDT) Market Performance Summary for February 26, 2026

Stock Performance Overview

On February 26, 2026, Medtronic Public Limited Company (MDT) experienced a slight decline in its stock price. The key metrics for the day are as follows:

• Opening Price: $96.32
• Current Price: $96.65
• Previous Close: $96.75
• Change: -$0.10
• Percentage Change: -0.10%
• Highest Price of the Day: $97.39
• Lowest Price of the Day: $95.90
• Trading Volume: Approximately 6.56 million shares

The stock opened at $96.32, reached a high of $97.39, and a low of $95.90 throughout the trading session. The trading volume indicates significant activity, with around 6.56 million shares exchanged.

Recent News and Events Impacting MDT Stock

1. Earnings Report: Medtronic recently reported its fiscal third-quarter earnings on February 17, 2026. The company achieved earnings per share (EPS) of $1.36, surpassing analyst expectations of $1.34. Revenue for the quarter was reported at $9.02 billion, reflecting an increase of 5.8% year-over-year, which also exceeded the expected $8.89 billion. This strong performance highlighted the highest revenue growth in ten quarters.
2. Analyst Ratings: Following the earnings report, analysts provided mixed ratings. Notably, Robert W. Baird lowered their price target from $103.00 to $100.00 while maintaining a "neutral" rating. Conversely, Mizuho upgraded their rating to "strong buy." Overall, Medtronic holds 1 Strong Buy, 15 Buy ratings, and 10 Hold ratings, with an average target price of $110.84.
3. Acquisition of Shares: On February 25, 2026, it was reported that Magellan Asset Management Ltd acquired 1,326,614 shares of Medtronic, valued at approximately $126.35 million. This acquisition represents about 1.5% of their portfolio, indicating institutional confidence in Medtronic's long-term prospects.
4. Market Sentiment: Despite the positive earnings report, Medtronic's stock price has shown volatility. The mixed analyst ratings and recent adjustments in price targets have contributed to a cautious market sentiment. Analysts have noted potential margin pressures that could affect future earnings.
5. Strategic Developments: Medtronic is also moving forward with the initial public offering (IPO) of its diabetes unit, MiniMed, which aims to raise approximately $784 million. This strategic pivot could enhance shareholder value and provide additional capital for growth initiatives.
6. Regulatory Approvals: The company has secured regulatory approvals for new gastrointestinal products, which are expected to support durable revenue streams and contribute positively to future earnings.

Conclusion

Medtronic's stock performance on February 26, 2026, reflects a combination of strong earnings results and mixed analyst sentiment. While the company reported robust revenue growth, the stock's slight decline indicates market caution, influenced by recent analyst ratings and broader market conditions. As Medtronic continues to navigate its strategic initiatives, including the MiniMed IPO and new product launches, investor attention will likely remain focused on the company's ability to sustain growth and manage margins effectively.

For the most accurate and real-time stock data, including closing prices, highest and lowest points, and trading volume, it is advisable to refer to reliable financial news platforms or Medtronic's official investor relations page.